247)
Introduction (777)
Heart failure (HF) is a complex and heterogeneous clinical syndrome, and in the last 10 years, two broadly defined phenotypes have emerged: HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF). It is now clear that failure to resolve immune activation is central to the pathogenesis of HF, both HFrEF and HFpEF. In HFrEF, typically observed secondary to ischemic injury, cardiac cell death drives an initial immune response to induce scar formation, but failure to resolve inflammation can worsen long-term ventricular remodeling (Review: (1) ). In HFpEF, it has been proposed that comorbidities associated with metabolic syndrome induce peripheral inflammation that drives remodeling (Reviews (2) (3) (4) ). Clinically, targeting the innate immune response has shown some success.
The Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial demonstrated a reduction in recurring cardiovascular events by targeting interleukin-1b (IL-1b) in patients with a prior myocardial infarction and high C-reactive protein (5) . While the results of CANTOS are promising, successes targeting immune modulators have not been universal (6) , suggesting the need for better understanding of the immune response in HF and the identification new therapeutic targets.
Free fatty acid receptor 4 (Ffar4, GPR120) is a G-protein coupled receptor (GPR) that functions as a nutrient sensor for fatty acids (FA) to regulate metabolism and attenuate inflammation (7, 8) . The endogenous ligands for Ffar4 include medium and long chain (C10-C22), saturated (SFA), mono-unsaturated (MUFA), and poly-unsaturated fatty acids (PUFA), which bind the receptor with affinities in the low µM range. In terms of agonist efficacy, generally, PUFAs are full agonists, whereas SFAs are partial agonists (9) (10) (11) . Consistent with a primary role in regulating metabolism, Ffar4 is expressed in enteroendocrine cells in the GI tract (11) , a, b, and d-cells in the pancreas (11) (12) (13) , and both white and brown adipose (14, 15) .
However, Ffar4 is found in many additional tissues with high levels of expression in the lung, and lower levels of expression in brain, heart, taste buds, and immune cells, including macrophages (10, (16) (17) (18) . Ffar4 signals through both Gq/11 and barrestin-2 (bArr2) mediated pathways, which appears to be cell-type dependent (10, 17, 19, 20) . Interestingly, humans express two isoforms of Ffar4, short and long (Ffar4S, Ffar4L), differentiated by a 16 amino acid insertion in the third intracellular loop of the long-isoform, whereas other species express only one isoform, homologous to Ffar4S in humans (20) . The Ffar4L isoform only signals through b-Arr2 and is unable to activate Gq/11-mediated signaling (20) .
Currently, nothing is known about Ffar4 function in the heart. Previous studies have indicated that w3-polyunsaturated fatty acids (w3-PUFAs) signaling through Ffar4 attenuate inflammation and obesity (10) . Clinical studies indicate that w3-PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), improve outcomes in coronary heart disease (21) (22) (23) (24) (25) (26) and HF (27) (28) (29) (30) , but the mechanisms underlying this benefit remain unclear. In mice, we were the first to demonstrate that EPA prevents fibrosis and contractile dysfunction in response to pathologic stress in the heart, but EPA was not incorporated into cardiac myocytes or fibroblasts, the traditional mechanism of action for EPA (16, 31) . However, we found that Ffar4 is expressed in cardiac myocytes and fibroblasts, and that in cardiac fibroblasts, Ffar4 was sufficient and necessary to prevent TGFb1-induced fibrosis (16) . These finding suggest that Ffar4 might mediate w3-PUFA cardioprotection. However, to date, no studies have directly addressed the function of Ffar4 in the heart, nor any link to w3-mediated cardioprotection.
Based on these findings, we hypothesized that Ffar4 is a cardioprotective nutrient sensor for medium and long chain fatty acids that resolves inflammation to maintain cardiac homeostasis. To test this hypothesis, we employed mice with systemic deletion of Ffar4 (Ffar4KO mice) to determine if Ffar4 is necessary for an adaptive response to pathologic pressure overload induced by transverse aortic constriction (TAC). Here, we report that TAC induced more severe remodeling in Ffar4KO mice, identifying, for the first time, an entirely novel cardioprotective role for Ffar4 in the heart. In cardiac myocytes, Ffar4 signaling through the cPLA2a-Cytochrome P450hydroxylase (CYPhydroxylase) axis specifically induced production of the EPA-derived oxylipin 18-hydroxyeicosapentaenoic acid (18-HEPE), the precursor to E-resolvins, a class of inflammation resolving oxylipins. Ffar4-mediated production of 18-HEPE was absent in Ffar4KO cardiac myocytes, providing a potential mechanism to explain the worse remodeling in the Ffar4KO post-TAC. Systemically, loss of Ffar4 altered oxylipin content in circulating plasma lipoproteins characterized by a loss of an anti-inflammatory oxylipins at baseline, and inability to produce both pro-inflammatory and pro-resolving oxylipins following TAC. Finally, we confirmed that Ffar4 is expressed in human heart and down-regulated in heart failure. In summary, our data suggest an entirely novel paradigm whereby FAs function as signaling molecules that activate GPR signaling through Ffar4 to resolve inflammation and maintain cardiac homeostasis.
Methods

Mice
For this study, all experimental mice were placed on a control diet (described below) at 8 weeks of age. At 12 weeks, male and female, WT and Ffar4KO mice were randomized and enrolled into the study. For all experimental analyses, data collection was done with investigator blinded to genotype and treatment.
All procedures on animals conformed to the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals and were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota.
Ffar4KO mice were generated from cryopreserved sperm from C57Bl/6N- 
Transverse Aortic Constriction (TAC)
Transverse aortic constriction (TAC) surgery was performed as previously described (16, (31) (32) (33) (34) . Baseline measurements of cardiac function by echocardiography were collected prior to surgery. For surgery, mice were anesthetized with 3% isoflurane and maintained at 1.5% isoflurane without intubation. A small incision was made slightly left of the midline and above the left clavicle without entering the pleural cavity. The muscle tissue and lobes of the thymus were retracted to expose the aortic arch. A 7-0 surgical suture was threaded under the aortic arch and tied-off against a small piece of a blunt 28-gauge needle followed by immediate removal of the needle. To close the original incision, the muscle layer and skin were secured separately with 4-0 continuous sutures. Buprenorphine (0.1 mg/kg IP) was administered for pain management during the first 24 hours post-surgery and as needed thereafter. Sham surgery was identical except for ligation of the aorta. Pulsed-wave Doppler by echocardiography was used to confirm pressure gradients by evaluating aortic flow velocity (AoV, Supplemental  Tables   3B  and  4B ) 7-days post-surgery at the site of constriction.
Measurement of cardiac function by echocardiography
Echocardiography was performed before TAC (baseline), 7-days post-TAC to measure aortic velocity (AoV) to validate the TAC surgery, and 4 weeks post-TAC using the Vevo 2100 Pulsed-wave Doppler images of the aortic arch were recorded at the site of constriction to measure peak aortic velocity (AoV) and pressure gradient (PG: (4*AoV 2 )/1000). Pulsed-wave Doppler images of the apical four-chamber view were taken to measure mitral flow velocities (E wave and A wave to calculate E/A ratio) as well as mitral annulus tissue velocity (E/E': peak early transmitral flow velocity/peak early diastolic mitral annular velocity).
Isolation and culture of adult cardiac myocytes
We previously described procedures for the isolation and culture of adult mouse cardiac myocytes (35) . Here, myocytes were isolated 3-days post-TAC from male WT and Ffar4KO, sham and TAC operated mice for analysis of myocyte transcriptomes, or were cultured from WT procedures for isolation and culturing of adult mouse ventricular myocytes (AMVM) and a detailed diagram of the perfusion apparatus were described in detail previously (35) . Based on our previous experience, myocyte isolation are ~95% pure, but we cannot exclude the possibility of minimal contamination with fibroblasts and endothelial cells (35) . Following plating, myocytes were counted at a magnification of 20X to determine cell viability, and myocytes were incubated in a 4.5% CO2 incubator at 37°C overnight. For analysis of Ffar4 signaling, cardiac myocytes were treated with the Ffar4 agonist TUG-891(Cayman Chemical, MI, USA) (50 µM) for 0-60 minutes.
Quantification of erythrocyte FA composition
At the study endpoint, blood from the posterior vena cava was collected into EDTA tubes. Red blood cell fractions were separated and analyzed for fatty acid composition as previously described (16, 31) . Briefly, 50 µL of isolated erythrocytes were methylated with 14% boron trifluoride in methanol by incubation for 10 minutes at 100°C. Fatty acid methyl esters were extracted in hexane and analyzed by a GC-2010 gas chromatography system fitted with a QP2010 mass spectrometer (Shimadzu, Japan) using a Supelco SP-2560 fused silica column (Supelco, Bellefonte, PA). Area counts were obtained using Shimadzu GCMSolution software with multiple ion counts of characteristic fatty acids ions. Each fatty acid was quantified as mass percent of total fatty acids. In general, only minor differences in red blood cell fatty acid composition were detected between WT and Ffar4KO following TAC (Supplemental Table  2 ).
Tissue histology
Four weeks after TAC surgery, hearts were arrested in diastole with 60mM KCl, excised, and weighed. Extracted hearts were cannulated and perfused with PBS with 60mM KCl, followed by 4% paraformaldehyde. The atria were removed from the fixed hearts prior to embedding in paraffin. Sectioning was performed by AML Laboratories (Jacksonville, FL) providing a transverse view of the ventricles. Lungs were also collected and lung weights were recorded.
Paraffin embedded ventricular sections were deparaffinized with xylene and rehydrated in ethanol. Sections were stained in 0.1% solution of Sirius red (direct red 80, Sigma-Aldrich, St Louis, MO) and fast green (Sigma-Aldrich) in 1.2% picric acid (Ricca Chemical Company, Arlington, TX), followed by dehydration in ethanol and xylene. Sections were imaged at 4x magnification. Ventricular fibrosis (as percent of total ventricular area) was quantified using Fiji software (NIH) (16, 31) . Ventricular fibrosis was quantified using images captured at 4X magnification and included both the right and left ventricle. The threshold settings were adjusted to highlight and calculate the total tissue area or picrosirius red positively stained area.
Oxylipin analysis
Plasma lipoproteins were separated by FPLC followed by measurement of esterified oxylipin (HDL, LDL, and VLDL) or unesterified (albumin). 150 µL of mouse EDTA plasma was thawed and filtered by centrifugation at 10,000 g for 5 min using Ultrafree Durapore PVDF filter Samples were analyzed by liquid chromatography using a Waters Acquity UPLC coupled to Waters Xevo triple quadrupole mass spectrometer equipped with electrospray ionization source (Waters, Milford, MA). 5 µL of the extract was injected and separation was performed using a CORTECS UPLC C18 2.1 x 100 mm with 1.6 µM particle size column. Flow rate was set at 500 µL/min and consisted of a gradient run using water with 0.1% acetic acid (Solvent A) and acetonitrile isopropanol, 90:10 (Solvent B) for 15 minutes (0-12 min from 25% B to 95% B, 12-12.5 min 95% B, 12.5-15 min 25% B). Electrospray ionization operated in negative ion mode with capillary set at 2.7 kV, desolvation temperature set at 600 °C, and source temp set to 150°C. Optimal oxylipin MRM transitions were identified by direct injection of pure standards onto the mass spectrometer and using cone voltage and collision energy ramps to optimize detection and most prevalent daughter fragments. Calibration curves were generated prior to each run using standards for each oxylipin. Peak detection and integrations were achieved through Target Lynx (Waters, Milford, MA) and each peak inspected for accuracy and corrected when needed.
RNA-seq:
Three days after surgery, cardiac myocytes were isolated from WT sham (n=4), WT TAC WT sham compared to WT TAC animals (2789 genes) and 2.) Ffar4KO sham compared to Ffar4KO TAC animals (1656 genes). The lists were compared to each other to identify genes that overlapped between the two lists to identify common genes (1409) and those genes that were unique to the WT mice (1380 genes) and Ffar4KO mice (247 genes). The genes were further annotated in CLCGW based on Gene Ontology (GO) terms for biological function from MGI. Genes were further sorted based on the indicated GO Terms into eight categories.
Principal component analyses used CPMs that were filtered based on gene size (excluding genes less than 200bp) and variance less than 1 in raw read counts. The actual cpm values are log2 transformed and plotted using the PCA function in R.
RT-PCR for Ffar4 and Ffar1 expression in heart
Human heart samples: Ventricular myocardium was obtained from non-failing and failing human hearts through the Duke Human Heart Repository (DHHR) as previously described (36 Figure  4 ) or within mouse lipoprotein differences ( Figure  5 ).
Statistical significance is indicated as a p value less than 0.05;; Tukey's test was used to test for specified post-hoc differences using JMP version 13.2.1.
Results
Ffar4 is necessary to mitigate the pathologic hypertrophic response induced by TAC
To test the hypothesis that Ffar4 is cardioprotective, wild-type (WT) and Ffar4KO mice were subjected to TAC, a model of pathologic pressure overload. After four weeks, TAC induced an exaggerated hypertrophic response in male Ffar4KO mice relative to WT, indicated by an increase in heart weight (HW) and heart weight-to-body weight ratio (HW/BW), with no significant difference in BW ( Figures  1A  and  B and Supplemental  Table  3A ). Based on our prior studies demonstrating that in cultured fibroblasts, Ffar4 is sufficient and necessary to prevent TGFb1-induced fibrosis, we expected that TAC would produce more fibrosis in the Ffar4KO.
However, we were surprised to find that TAC produced similar levels of fibrosis in WT and
Ffar4KO hearts ( Figures  1C  and  D) . TAC also caused a trend towards increased lung weights (LW) in male Ffar4KO mice, which is consistent with a worsened response to TAC ( Figure  1E ).
Unexpectedly, the exaggerated hypertrophic response observed in male Ffar4KO mice, was not observed in female Ffar4KO mice. In female mice, TAC induced a similar degree of hypertrophy in WT and Ffar4KO mice, with no significant differences detected in HW, fibrosis, or LW ( Figures  1F-H , Supplemental  Table  4A ).
Ffar4 is necessary to attenuate systolic and diastolic dysfunction induced by TAC After four weeks, TAC induced more significant systolic and diastolic dysfunction in male Ffar4KO mice relative to WT, indicated by a more dramatic decrease in ejection fraction (EF, Figure  2A ) and a greater increase in E/A ratio ( Figure  2B) . TAC had only a minor effect on ventricular geometry, with only a trend towards increased end-diastolic and end-systolic volumes (EDV, ESV) ( Figures  2C-D , Supplemental  Table  3B ). However, these results do suggest that male Ffar4KO mice might be progressing to greater eccentric remodeling. In female Ffar4KO and WT hearts, TAC induced a similar degree of systolic and diastolic dysfunction. However, EDV and ESV were both significantly increased, the only significant effects observed in female Ffar4KO mice (Figures  2E-H) .
In summary, our results demonstrated that TAC induced a more severe remodeling response in male Ffar4KO mice, indicating for the first time that Ffar4 is necessary for an adaptive response to pathologic stress in the heart. The surprising lack of an exacerbated fibrotic response in the Ffar4KO, as we previously predicted, would indicate that the more severe remodeling observed in the Ffar4KO heart was most likely due to the lack of cardioprotective Ffar4 signaling in cardiac myocytes. Our results also indicated the potential for a significant sex-based difference in the requirement for Ffar4 in response to pathologic stress in the heart. There are two potential explanations for this sex-based difference;; 1.) The response to TAC in female WT mice was greater than male WT mice (58% increase in HW, revealed only minor differences in the transcriptomes between genotypes, whereas much larger differences were induced by surgery ( Figure  3A ). However, a separate analysis of genes specifically regulated by TAC in either WT or Ffar4KO cardiac myocytes identified substantial differences in the number of genes differentially expressed post-TAC depending on genotype ( Figure  3B ). TAC altered expression of 2,789 genes (up or down) by 1.7-fold or more in WT cardiac myocytes, whereas TAC changed expression of only 1,656 genes in Ffar4KO myocytes.
Comparison of these lists revealed 1409 genes were common between the two genotypes, whereas 1380 genes were unique to WT cardiac myocytes, but only 247 genes were unique to Ffar4KO myocytes. ( Figure  3B ). Individual genes from each genotype were further sorted by Gene Ontology terms for biological function for eight different categories that reflect cardiac myocyte biology;; cell death, inflammation, contractile function, angiogenesis, fibrosis, GPR, fatty acid metabolism, and hypertrophy ( Figure  3C , Supplemental  Tables  5-12 ). Genes categorized by biological function for cell death and inflammation had the most differentially expressed genes, with significantly more genes identified in WT cardiac myocytes ( Figure  3C , Table  1 ). Interestingly, we also identified genes specifically associated with activation of cPLA2a signaling, an Ffar4 signaling pathway in macrophages (37), were induced in WT, but not Ffar4KO cardiac myocytes ( Figure  3D , Table  1 ). In summary, transcriptome analysis three days post-TAC suggested that cardiac myocytes from Ffar4KO hearts were unable to induce the same inflammatory and cell death responses as WT animals, specifically genes associated with cPLA2a signaling, likely contributing to the more severe remodeling in the Ffar4KO post-TAC.
Ffar4 agonist TUG-891 increases production of 18-HEPE in adult cardiac myocytes
To define the function of Ffar4 in cardiac myocytes, we focused on Ffar4 mediated activation of cPLA2a, based on the results from our transcriptome analysis. Upon activation, cPLA2a can translocate to the nuclear membrane and cleave PUFAs from the sn2-acyl bond in membrane phospholipids, traditionally arachidonic acid (AA), but also EPA, DHA, or other PUFAs (38) . Cleaved FAs are subsequently metabolized to produce oxylipin products with proinflammatory, anti-inflammatory, or pro-resolving effects. In adult cardiac myocytes treated with the Ffar4 agonist TUG-891, we used UPLC/MS/MS to detect specific AA, EPA, and DHA derived oxylipin production to assess cPLA2a activity (Figure  4 A-H). Here, oxylipins produced following TUG891 treatment were considered to have one of four fates: 1) acylation into cellular membranes (esterified, myocyte);; 2) free in the myocyte (unesterified, myocyte);; 3) export in esterified lipids (esterified, medium);; or 4) exported as a free oxylipin (unesterified, medium) ( Figure  4I ). We identified 57 different oxylipins in our samples, with details for MRM transitions, retention times, detection parameters, and detection limits presented in Supplemental  Table  13 .
Results for all oxylipins at 60 minutes are reported in Supplemental  Table  14 . Surprisingly, we found that TUG-891 selectively increased the production of the EPA-derived oxylipin 18-HEPE, likely by means of CYPhydrox activity in cardiac myocytes (esterified 18-HEPE, Figure  4A and unesterified 4B) and exported from myocytes (esterified 18-HEPE, Figure  4C and unesterified 4D), over time ( Figures  4E-H) .
The Ffar4-depedent increase in 18-HEPE occurred despite AA abundance being much higher, suggesting a previously unrecognized specificity for cPLA2a function. One explanation for the specific increase in 18-HEPE production could be a relative enrichment of EPA at the nuclear membrane. Because cPLA2a can translocate to the nuclear membrane (NM) upon activation ( Figure  4I) , we compared the relative substrate availability in the NM to the sarcolemma/plasma membrane (PM) to determine how this affect the relative availability of PUFAs to oxylipin producing enzymes. %EPA was lower than %DHA or %AA in both PM and NM fractions, however the relative abundance of EPA was 11.5-fold greater in NM compared to PM ( Figure  4J ). In contrast, %DHA and %AA were lower in NM (2.3 and 1.6 fold less, respectively) compared to PM, for a total increase in the relative availability of EPA to cPLA2a of approximately 26-fold relative to DHA and 19-fold relative to AA.
Loss of Ffar4 changes circulating oxylipin content consistent with a loss of antiinflammatory oxylipins at baseline, and prevents initiation of both mediators of inflammation and of resolution following TAC.
AA, EPA, and DHA oxylipins are produced intracellularly but are exported and trafficked in plasma in lipoproteins (39, 40) . Therefore, we examined the consequences of disruption of Supplemental  Table  15 ;; tests across all relevant PC scores are given in Supplemental  Table  16 , and tests across all individual oxylipins are given in Supplemental  Table  17 .
All albumin fractions were located leftward, or negatively, away from all oxylipins indicating the low concentration of unesterified, freely circulating, oxylipins ( Figure  5A) . A small adaptive response to TAC surgery in Ffar4KO animals was evidenced by a rightward shift from the Ffar4KO sham location to co-localizing with WT sham and WT TAC.
In all lipoproteins, TAC was associated with an adaptive response in WT mice. For HDL, the oxylipin content of HDL from WT sham mice were located rightward towards 14 (15) In a similar fashion, in WT mice, LDL oxylipin profiles indicated an adaptive response following TAC, but not in Ffar4KO mice. Relative to HDL, LDL were generally located more leftward, indicating they contained less oxylipins than HDL, consistent with our prior observations in humans (39, 41) . LDL from WT sham mice ( Figure  5C ) were located rightward towards 14(15)-EpETE, while LDL from WT TAC mice moved leftward, away from all oxylipins, consistent with a loss of oxylipin content, co-localizing with LDL from both Ffar4KO sham and TAC mice. This suggested that the loss of Ffar4 pre-disposed towards conditions that were only present in the WT mouse following surgery.
Like LDL, VLDL were more centrally located than HDL, which is evidence of their lower overall oxylipin content relative to HDL, again consistent with prior observations in humans (39, 41) . VLDL from WT sham mice ( Figure  5D ) were located most rightward, reflecting their high concentrations of anti-inflammatory epoxides such as 14 (15) 18-HEPE response to Ffar4 activation was reflected in plasma oxylipin pools, and most 18-HEPE was found in the HDL fraction ( Figure  5F ). Interestingly, 18-HEPE was dramatically lower in the Ffar4KO HDL fraction at baseline (sham), and although it increased following TAC, it never reached levels observed in the WT. In both LDL and VLDL fractions, 18-HEPE was lower in the Ffar4KO sham, and following TAC, while 18-HEPE levels decreased in the WT, 18-HEPE levels actually increased in the Ffar4KO.
Ffar4 is expressed in the human heart and downregulated in HF, with reciprocal upregulation of Ffar1.
Similar to mice, nothing is known about Ffar4 in the human heart. Therefore, we used RT-PCR to measure Ffar4 expression in samples from both healthy donors and HF patients.
We found that while human hearts do express Ffar4, Ffar4 (Ffar4S + Ffar4L) expression is reduced in failing hearts, and Ffar4L represents less than 10% of total Ffar4 expression, and was not changed following TAC ( Figure  6 ). Unexpectedly, expression of Ffar1, the only other known GPR for medium- and long-chain fatty acids, was reciprocally increased in failing hearts relative to healthy controls. This represents a significant difference from the mouse heart, which does not express detectable levels of Ffar1 (16) .
Discussion (1438)
Here, we show for the first time that Ffar4 is cardioprotective and necessary for an adaptive response to pathologic stress in the heart. This is supported by our findings that in Ffar4KO mice, TAC induced an exaggerated hypertrophic response, although with a similar degree of fibrosis, as well as greater systolic and diastolic dysfunction, indicating worse pathologic remodeling. Furthermore, Ffar4-mediated cardioprotection occurred independent of any dietary intervention implying that Ffar4 is able to sense and respond to basal fatty acid composition to protect the heart. Mechanistically, transcriptome analysis of cardiac myocytes three days post-TAC revealed programmatic changes in gene expression associated with inflammation and cell death were lacking in Ffar4KO cardiac myocytes. More importantly, we observed specific deficits in genes associated with cPLA2a-mediated signaling responsible for oxylipin production in Ffar4KO cardiac myocytes. In cultured cardiac myocytes, we were surprised to find that Ffar4 preferentially increased production of one cardioprotective, EPAderived oxylipin, 18-HEPE, despite the generally low levels of EPA detected in cardiac myocyte membranes at baseline. Furthermore, profiling oxylipin content in plasma, both esterified in circulating lipoproteins and unesterified (bound to albumin), generally indicated that loss of Ffar4 was associated with lower overall oxylipin content in all plasma fractions, and specifically less anti-inflammatory oxylipins at baseline, and inability to increase pro-inflammatory and proresolving oxylipins following TAC. Together, these results suggest that a key mechanism to explain the cardioprotective effects of Ffar4 is through induction of pro-resolving oxylipins in cardiac myocytes directly, and through indirect effects in balancing pro-inflammatory and proresolving oxylipin composition systemically, consistent with failure to activate cPLA2a.
Additionally, we demonstrated that Ffar4 is expressed in the human heart, and downregulated in HF. In summary, our data suggest that Ffar4 functions as a nutrient sensor for medium and long chain fatty acids to resolve inflammation and maintain cardiac homeostasis.
Transcriptome analysis of cardiac myocytes performed three days post-TAC identified a deficit in cPLA2a signaling in Ffar4 cardiac myocytes (Figure  3 ) (38) . There are six cPLA2 family members (a, b, g, d, e, and z), which show only roughly 30% sequence homology, but have different enzymatic properties, tissue expression, and subcellular localizations (38) . cPLA2a is widely expressed and has biologic functions in a multitude of cell types (38) and upon activation, it localizes to the nuclear membrane (42) . Early studies suggested that cPLA2a functions as a negative regulator of striated muscle growth. In mice with systemic deletion of cPLA2a (cPLA2KO mice), normal developmental growth of skeletal and cardiac muscle, as well as pathologic cardiac hypertrophic growth post-TAC are exaggerated (43) . Mechanistically, loss of cPLA2a induced sustained activation of IGF-1 signaling, a known hypertrophic stimulus, in cardiac myocytes from cPLA2KO hearts (43) . In addition, cPLA2a might protect against ischemic injury in the heart, although there are conflicting reports regarding cPLA2a -mediated cardioprotection (44, 45 (46) . Here, we found that in cardiac myocytes, the Ffar4 agonist TUG-891 activated cPLA2a and induced the production of a specific EPA-derived oxylipin, 18-HEPE (Figure  4 , Supplemental  Tables  14) . Although, the specific source of 18-HEPE is unknown, it is likely a product of CYPhydroxylase activity (47) . Our data imply a role for Cyp26b1 which is previously identified for its role in hydroxylating retinoic acid (48) . While this is the first such demonstration in cardiac myocytes, one previous study in macrophages indicated that DHA signaling through Ffar4 activates cPLA2a mediated oxylipin production (37) . Interestingly, we found EPA levels in red blood cells were low, 0.1-0.2% of total membrane FAs, whereas DHA was 4% and AA was 13% ( Supplemental  Tables  2A  and  2B ), similar to our previous studies (16) . Furthermore, we previously found that in cardiac myocytes, EPA was 0.5% of total membrane FAs, whereas DHA was 10% and AA was about 12% (16) .
Therefore, in cardiac myocytes, Ffar4 shows surprising degree of specificity for the production of 18-HEPE, largely to the exclusion of other EPA, DHA, or AA derived oxylipins despite the low levels of EPA in cardiac myocyte membranes. Potentially, the localization of cPLA2a to an EPA rich membrane enhances its capacity to mediate the specific production of EPA-derived oxylipins such as 18-HEPE.
While there are no previous studies regarding the direct effects of 18-HEPE in cardiac myocytes, macrophages from fat-1 mice, which have high endogenous levels of w3-PUFAs, particularly EPA, due to overexpression the c. elegans fat-1 gene, produced high levels of 18-HEPE that were associated with cardioprotection in fat-1 mice post-TAC (49) . Furthermore, direct i.p. injection of 18-HEPE attenuated remodeling post-TAC (49) . Interestingly, 18-HEPE is also the precursor for E-series resolvins (RvE1, RvE2, and RvE3), a class of pro-resolving oxylipins (50) . E-resolvins signal through ERV1/ChemR23, an orphan GPR that binds to and is activated by both E-resolvins and the endogenous peptide chemerin, suggesting a potential mechanism to explain EPA-mediated inflammation resolving effects (51) . ERV1/ChemR23 is expressed in the heart, and preconditioning with RvE1 reduces ischemia/reperfusion injury (52) , while RvE1 infusion one-week following coronary artery ligation attenuates post-MI inflammatory response (53) . In our study, the production of 18-HEPE co-occurred systemically with the production of pro-inflammatory products, 12-HETE and 15-HETE. Combined with our data, these studies suggest that Ffar4-cPLA2a mediated production of 18-HEPE is cardioprotective by providing the capacity to resolve inflammation, either through direct effects in the heart, released from infiltrating macrophages or directly produced in cardiac myocytes, or indirect effects via production of E-resolvins and activation of ERV1/ChemR23.
Two important deficits were observed in circulating oxylipin profiles in Ffar4KO mice:
first, Ffar4KO mice lacked the capacity to induce any cPLA2a mediated oxylipin response, and second, they lacked the capacity to modify oxylipin production in response to TAC. Surprisingly, this did not mean suppressing the activation of inflammation, but instead it meant co-producing mediators essential for the resolution of inflammation. Systemically, WT mice at baseline (sham) had the highest oxylipin content, with high levels of anti-inflammatory oxylipins such as 14 (15) (56) . We found that despite increase in this pro-inflammatory insult (increased 12-HETE, 15-HETE), WT mice were protected through their capacity to co-produce the pro-resolving 18-HEPE, which was lacking in Ffar4KO mice. This suggests that the capacity to produce 12/15-LOX metabolites is beneficial, provided they can also initiate recovery.
Clinically, w3-PUFAs are important to cardiovascular health (57, 58) , and there is substantial evidence demonstrating a benefit of w3-PUFAs in coronary heart disease (CHD) and HF. In one large clinical trial, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico-Heart Failure (GISSI-HF) (27) , and several smaller trials, w3-PUFAs improved HF outcomes (28) (29) (30) . In animal models, we have also demonstrated that EPA, in a concentrationdependent manner, prevents pathologic remodeling post-TAC (16, 31, 59) . However, important questions remain regarding the mechanism underlying the benefit of w3-supplementation in HF.
Here, we found that Ffar4, a receptor for medium and long-chain fatty acids including, but not limited to, w3-PUFAs, is cardioprotective, but whether Ffar4 is required for w3-mediated protection is unclear at this time. Mechanistically, we found that in cardiac myocytes Ffar4 increased 18-HEPE levels, which might be directly cardioprotective or act through its downstream metabolites E-resolvins. Ultimately, this could suggest a feed-forward mechanism with multiple points for EPA mediated cardioprotection: 1. Through Ffar4-mediated production of 18-HEPE, either in cardiac myocytes ( Figure  4 ) or potentially macrophages (37). 2. Increasing overall EPA levels, thereby increasing 18-HEPE levels, as suggested by others (49), or 3.
Increased E-resolvin levels and activation of ERV1/ChemR23 either via Ffar mediated production of 18-HEPE or increased 18-HEPE levels secondary to an overall increase in EPA levels.
In conclusion, our results identify Ffar4 as a nutrient sensor for medium and long chain FAs that attenuates inflammation to maintain cardiac homeostasis. Finally, our findings suggest a novel paradigm for FAs in cardiac myocytes, whereby FA function not simply as an energy source, but as signaling molecules that activate cardioprotective GPR signaling. (50µM) for 0, 15, 30, and 60 minutes. Oxylipins were detected by mass spectrometry from cardiac myocyte membranes (esterified) or cytosolic fractions (non-esterified, or from the culture medium in lipoproteins (esterified) or free (non-esterified). Probability plots for oxylipins detected from cardiac myocytes in the A, esterified or B, unesterified fractions after 60 minutes, or in the culture medium in the C, esterified or D, unesterifed fractions, or time course of 18-HEPE production in myocytes in the E, esterified or F, unesterifed fractions, or in the medium in the G, esterified or H, unesterified fractions (dashed lines represent the 95% CI). I, Cytoplasmic phospholipase A2a (cPLA2a) mediated cleavage of EPA from membrane phospholipids and production of 18-HEPE by CYPhydrolase. 18-HEPE is re-acylated into membrane phospholipids (sequestration), remains free in the cell and is further metabolized (potentially E-Resolvins), or exported, esterified in a lipoprotein. J, EPA, DHA, and AA concentration in the nuclear membrane (NM) or sarcolemma/plasma membrane (PM). Data are Mean ± SD, n=3 separate preparations, fold differences indicated. Figure  5 . Loss of Ffar4 changes circulating oxylipin content consistent with a loss of anti-inflammatory oxylipins at baseline, and prevents initiation of both mediators of inflammation and of resolution following TAC. 
